Richard Giroux serves as the Chief Financial Officer (CFO) and Chief Operating Officer (COO) at MEIRAGTX HOLDINGS PLC, a clinical-stage gene therapy company focused on developing treatments for serious diseases. In his dual role, Giroux is responsible for overseeing the company's financial operations and strategic planning, as well as managing the day-to-day operations and ensuring the efficient execution of the company's business objectives. His leadership has been instrumental in guiding MEIRAGTX through its growth and development stages, positioning the company as a key player in the gene therapy industry. Prior to joining MEIRAGTX, Giroux held several high-level financial and operational positions in the biotechnology and pharmaceutical sectors. He has a proven track record of successfully managing complex financial portfolios and driving operational excellence. Among his notable achievements, Giroux played a pivotal role in securing significant funding for MEIRAGTX, enabling the company to advance its research and development programs. His strategic vision and financial acumen have been crucial in navigating the challenges of the competitive biotech landscape and in fostering partnerships that enhance the company's capabilities and reach. Giroux's extensive experience and expertise in finance and operations make him a valuable asset to MEIRAGTX. His commitment to innovation and excellence continues to drive the company forward, as it works towards bringing transformative gene therapies to patients in need. Under his leadership, MEIRAGTX is well-positioned to achieve its mission of developing and commercializing groundbreaking treatments for serious genetic diseases.